Search research articles
Contact Us
Filters
Showing results (181-190 of 436) with videos related to
Page
of 44
Sort By:
American Journal of Hematology
|
July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients
Gautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Cancer
|
June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia
Kamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
Cancer
|
December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
American Journal of Hematology
|
May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome
Talha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
American Journal of Hematology
|
May 2, 2020
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin
Nicholas J Short, Guillaume Richard-Carpentier, Rashmi Kanagal-Shamanna, et al.
Blood Advances
|
January 21, 2022
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R Wilson, Guillermo Garcia-Manero, et al.
Blood Advances
|
July 24, 2023
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
Mary Figueroa, Huaxian Ma, Mansour Alfayez, et al.
Cancer
|
March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia
Alexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
American Journal of Hematology
|
November 5, 2014
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia
Tapan M Kadia, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood Neoplasia
|
June 2, 2025
Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML
Samuel Urrutia, Prithviraj Bose, Yesid Alvarado, et al.
Page
of 44
Search research articles
Search
Showing results (181-190 of 436) with videos related to
Sort By:
Page
of 44
American Journal of Hematology
|
July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients
Gautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Cancer
|
June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia
Kamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
Cancer
|
December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
American Journal of Hematology
|
May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome
Talha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
American Journal of Hematology
|
May 2, 2020
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin
Nicholas J Short, Guillaume Richard-Carpentier, Rashmi Kanagal-Shamanna, et al.
Blood Advances
|
January 21, 2022
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R Wilson, Guillermo Garcia-Manero, et al.
Blood Advances
|
July 24, 2023
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
Mary Figueroa, Huaxian Ma, Mansour Alfayez, et al.
Cancer
|
March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia
Alexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
American Journal of Hematology
|
November 5, 2014
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia
Tapan M Kadia, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood Neoplasia
|
June 2, 2025
Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML
Samuel Urrutia, Prithviraj Bose, Yesid Alvarado, et al.
Page
of 44